한글목차

세계의 전임상 CRO 시장 규모는 2024년에 62억 4,000만 달러로 평가되었고, 2030년에는 101억 5,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 8.45%를 보일 것으로 예측됩니다.

이 시장은 제약, 바이오기술, 의료기기 기업들이 전임상 연구 활동을 수행하는 데 필수적인 서비스를 제공함으로써 의약품 개발 생태계에서 중요한 역할을 담당하고 있습니다. 전임상 CRO는 생물학적 분석, 독성학, 안전성 약리학, 화합물 관리 등 다양한 서비스를 제공하여 고객이 규제 요건을 충족시키며 효율성과 비용 효율성을 향상시키는 데 도움을 줍니다. 초기 단계 연구의 아웃소싱 증가로 인해 기업들이 운영을 효율화하고 핵심 역량에 집중하려는 추세가 시장 성장을 촉진하고 있습니다. 약물 발견 노력의 증가, 연구 모델의 기술적 발전, 전문적인 과학적 전문성 수요의 증가는 지역별 시장 성장을 더욱 가속화하고 있습니다.

시장 성장 촉진요인

아웃소싱 동향 증가가 시장 성장을 주도

주요 시장 과제

규제 준수 및 품질 보증

주요 시장 동향

가상 임상 시험의 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 전임상 CRO 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 서비스별(생물학적 분석, 독성학, 안전성 약리학, 화합물 관리, 기타)
  • 모델 유형별(환자 유래 오가노이드(PDO) 모델, 환자 유래 이종 이식 모델)
  • 최종 이용 산업별(제약, 바이오기술, 의료기기 기업)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 전임상 CRO 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽 전임상 CRO 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 전임상 CRO 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미 전임상 CRO 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 전임상 CRO 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Eurofins Scientific SE
• PRA Health Sciences, Inc.
• Wuxi AppTec
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• SGA SA
• Intertek Group Plc
• LABCORP, Inc.
• Crown Bioscience Inc

제16장 전략적 제안

제17장 기업 소개와 면책사항

영문목차

The Global Preclinical CRO Market was valued at USD 6.24 billion in 2024 and is projected to reach USD 10.15 billion by 2030, growing at a CAGR of 8.45% during the forecast period. This market plays a crucial role in the drug development ecosystem by providing essential services that support pharmaceutical, biotechnology, and medical device companies in their preclinical research activities. Preclinical CROs offer a range of services including bioanalysis, toxicology, safety pharmacology, and compound management, helping clients meet regulatory requirements while improving efficiency and cost-effectiveness. The market is benefiting from the increased outsourcing of early-stage research, as companies seek to streamline operations and focus on core competencies. The rise in drug discovery efforts, technological advancements in research models, and demand for specialized scientific expertise are further driving market growth across regions.

Key Market Drivers

Increasing Outsourcing Trends Drives the Market Growth

A major growth driver for the Global Preclinical CRO Market is the increasing trend of outsourcing among pharmaceutical and biotechnology companies. By outsourcing preclinical R&D activities to specialized CROs, companies are able to significantly reduce costs associated with facility maintenance, personnel, and equipment. CROs offer advanced infrastructure and expert staff, allowing sponsors to accelerate timelines while ensuring regulatory compliance. This model also provides scalability, enabling companies to adapt to changing project demands without major internal investments. Moreover, CROs grant access to cutting-edge technologies and methodologies, helping clients improve research outcomes while focusing internal resources on clinical trials, regulatory strategies, and commercialization. As the demand for efficient and flexible research solutions continues to rise, outsourcing remains a preferred strategy, bolstering the growth of the preclinical CRO sector globally.

Key Market Challenges

Regulatory Compliance and Quality Assurance

The Global Preclinical CRO Market faces considerable challenges due to complex regulatory requirements and the need for strict quality assurance. Regulatory bodies such as the FDA and EMA impose rigorous standards that CROs must meet to ensure that studies are conducted ethically, accurately, and in compliance with international guidelines. Navigating diverse and evolving regulations across multiple geographies adds complexity, particularly for CROs working with global clients. Maintaining compliance requires ongoing investment in specialized personnel, documentation systems, quality audits, and training, which can strain operational resources. Delays or errors in regulatory adherence may lead to costly project setbacks or non-approval of drug candidates in later stages, underscoring the critical need for continuous regulatory vigilance and operational excellence in the CRO landscape.

Key Market Trends

Increase in the Number of Virtual Trials

A significant trend transforming the Global Preclinical CRO Market is the growing adoption of virtual or decentralized clinical trials, which leverage digital tools to collect patient data remotely. Although primarily impacting clinical phases, this trend is influencing preclinical CROs to expand their technological capabilities and align with integrated drug development models. CROs are now incorporating wearable devices, mobile apps, and telehealth platforms to facilitate remote monitoring and data collection, enabling smoother transitions from preclinical to clinical stages. These digital advancements enhance patient recruitment, diversify participation, and improve data accuracy. As a result, CROs are partnering with tech providers and investing in secure data infrastructure to support virtual research models, thereby optimizing trial efficiency and reducing dependency on traditional site-based models.

Key Market Players

• Eurofins Scientific SE
• PRA Health Sciences, Inc.
• Wuxi AppTec
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• SGA SA
• Intertek Group Plc
• LABCORP Inc.
• Crown Bioscience Inc

Report Scope:

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service:

• Bioanalysis and DMPK Studies
• Toxicology Testing
• Compound Management
• Chemistry
• Safety Pharmacology
• Others

Preclinical CRO Market, By Model Type:

• Patient Derived Organoid (PDO) Model
• Patient Derived Xenograft Model

Preclinical CRO Market, By End User Industry:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Preclinical CRO Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Bioanalysis and DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
  • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
  • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Preclinical CRO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Model Type
  • 6.2.3. By End-Use Industry
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Preclinical CRO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Model Type
      • 6.3.1.2.3. By End-Use Industry
  • 6.3.2. Mexico Preclinical CRO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Model Type
      • 6.3.2.2.3. By End-Use Industry
  • 6.3.3. Canada Preclinical CRO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Model Type
      • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Model Type
  • 7.2.3. By End-Use Industry
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Preclinical CRO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Model Type
      • 7.3.1.2.3. By End-Use Industry
  • 7.3.2. Germany Preclinical CRO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Model Type
      • 7.3.2.2.3. By End-Use Industry
  • 7.3.3. United Kingdom Preclinical CRO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Model Type
      • 7.3.3.2.3. By End-Use Industry
  • 7.3.4. Italy Preclinical CRO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Model Type
      • 7.3.4.2.3. By End-Use Industry
  • 7.3.5. Spain Preclinical CRO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Model Type
      • 7.3.5.2.3. By End-Use Industry

8. Asia-Pacific Preclinical CRO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Model Type
  • 8.2.3. By End-Use Industry
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Preclinical CRO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Model Type
      • 8.3.1.2.3. By End-Use Industry
  • 8.3.2. India Preclinical CRO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Model Type
      • 8.3.2.2.3. By End-Use Industry
  • 8.3.3. South Korea Preclinical CRO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Model Type
      • 8.3.3.2.3. By End-Use Industry
  • 8.3.4. Japan Preclinical CRO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Model Type
      • 8.3.4.2.3. By End-Use Industry
  • 8.3.5. Australia Preclinical CRO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Model Type
      • 8.3.5.2.3. By End-Use Industry

9. South America Preclinical CRO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Model Type
  • 9.2.3. By End-Use Industry
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Preclinical CRO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Model Type
      • 9.3.1.2.3. By End-Use Industry
  • 9.3.2. Argentina Preclinical CRO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Model Type
      • 9.3.2.2.3. By End-Use Industry
  • 9.3.3. Colombia Preclinical CRO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Model Type
      • 9.3.3.2.3. By End-Use Industry

10. Middle East and Africa Preclinical CRO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Model Type
  • 10.2.3. By End-Use Industry
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Preclinical CRO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Model Type
      • 10.3.1.2.3. By End-Use Industry
  • 10.3.2. Saudi Arabia Preclinical CRO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Model Type
      • 10.3.2.2.3. By End-Use Industry
  • 10.3.3. UAE Preclinical CRO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Model Type
      • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Eurofins Scientific SE
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. PRA Health Sciences, Inc.
• 15.3. Wuxi AppTec
• 15.4. Medpace, Inc.
• 15.5. Charles River Laboratories International, Inc.
• 15.6. PPD, Inc.
• 15.7. SGA SA
• 15.8. Intertek Group Plc
• 15.9. LABCORP, Inc.
• 15.10. Crown Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer